Coya is developing disruptive, first in class, autologous regulatory T-cell (Treg) and allogeneic exosome therapies - leveraging the seminal discoveries from the laboratory of Stanley Appel M.D., in which dysfunctional Tregs modulate neurodegenerative and autoimmune diseases.
Liberty University
8 followers
Dyno Therapeutics
4 followers
Cellares
5 followers
Gilead Sciences
204 followers
Regeneron
166 followers
Illumina
88 followers
Agilent Technologies
96 followers
Verily Life Sciences
49 followers
Alexion Pharmaceuticals
54 followers
GRAIL
35 followers
Springside Chestnut Hill Academy
35 followers